INNOVADERM CRO IS NOW INDERO.

Phase 3 Pediatric Atopic Dermatitis (AD) Study

Indero

Indero

Team of Experts

Author picture

Download PDF Version

Indero successfully managed this Phase 3 AD study, resulting in: 

  • Patient recruitment completed six and a half months early

  • Achieved same-day or next-day activation for most of the 47 sites

Indero had supported earlier clinical research that brought an effective therapy for atopic dermatitis (AD) in adults and children over the age of two onto the U.S. market. Indero was selected again for this Phase 3 study investigating the same drug for children ages three months to two years.

 

Study Characteristics 

Study Phase: 3

Study Design: 8-week randomized, double-blind placebo-controlled study followed by an open label extension (OLE) of 48 weeks 

Patient Population: Pediatric (three months to two years) AD 

IP Route of Administration: Topical 

Total Enrollment: 187 patients, 47 sites (United States & Canada) 

 

Challenges and Solutions 

Challenge #1: Insufficient sites serving target population 

Not enough dermatology sites were found whose patient base included an adequate number of babies with AD. 

Solution: Indero adjusted physician referral pathway, and conducted targeted recruitment campaign 

Indero identified that itchy babies are usually taken to an allergist, not a dermatologist, when a rash develops. Accordingly, Indero’s Site Selection Team adjusted the physician referral pathway to include allergists. This pivot was so successful that only 36 sites were needed out of the target 50 sites set by the sponsor. 

As well, Indero’s Patient Recruitment Team conducted a geo-targeted advertising campaign on social media, while leveraging Indero’s in-house Clinago platform. Increased awareness in the communities around selected sites, focusing on parents and caregivers of the patient population, resulted in identifying 14% of enrolled patients. 

Challenge #2: Same-day site activation required 

While the industry average for site activation time is one to two weeks, the sponsor in this study required same-day or next-day activation of sites. 

Solution: Indero’s agility achieved goal at most sites 

Through agile work processes, Indero aimed to achieve same-day or next-day activation for most of the sites activated, which met the sponsor’s requirement. 

Challenge #3: Sponsor acquisition brought many new faces 

An acquisition by the sponsor meant many new faces on the study. This resulted in some additional sponsor touchpoints between the new staff and Indero employees. 

Solution: Indero’s adaptable team

The sponsor appreciated the Indero project team that minimized the impact of sponsor staff changeover. Indero met all the extra touchpoints required. 

 

Strategies for Success 

  • Dermatologic expertise within Indero meant knowing which sites to select, resulting in exceeding patient enrollment goals and timelines.
  • Pivot to appropriate physician referral pathway by Indero’s site selection team to get the right investigators to read the right feasibility questionnaire. 
  • Leveraging Indero’s in-house Clinago platform and patient recruitment expertise to conduct an impactful central advertising campaign that accelerated enrollment. 
  • New study startup model customized for the sponsor by Indero’s study startup team.
SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

Fields marked with * are required.